Supernus: Revenue Up 32%, Earnings Negative. One Quarter Holds Both Facts.
The gist of it The Q2 2026 10-Q shows Supernus growing revenue at its fastest pace...
Amphastar: Three Good Numbers, Two Bad Letters, and a $100 Million Bill
For four straight years, Amphastar Pharmaceuticals ran one of the quieter success stories in generic drugs:...
Corcept Therapeutics: One Drug Fading, One Just Born, and a Stock Priced for Neither
For most of its life, Corcept Therapeutics was essentially a one-drug company. Korlym, its mifepristone pill...
Arrowhead’s Burning Runway Meets a Crowded Pipeline: Reading the Q3 2026 Filing
For most of its life, Arrowhead Pharmaceuticals was a company that spent money and promised science....
One drug, one billion dollars, and a clock ticking toward 2030
Harmony Biosciences went public in August 2020 selling a single approved drug to a small population...
Vertex: A $10 Billion Bet Lands the Same Week a New Drug Crosses $1 Billion
The gist of it The math shows a business that has grown revenue every year for...
USANA: The Cash Is Real, the Loss Is Not, and the Customer Count Is the Story
USANA built its business over three decades on a simple machine: recruit independent distributors, sell them...
Madrigal’s math says one thing. The price tag says another. The filings lay out what each side of that gap rests on.
Before anything else The math: Rezdiffra, Madrigal's liver-disease drug, went from essentially zero revenue to nearly...
Regeneron: The Drug That Keeps Growing, and the Trial That Didn’t
Regeneron spent most of the 2010s as a one-drug story, riding EYLEA's dominance in eye disease...
Trulieve: A $403 Million Loss That Isn’t What It Looks Like, and a Profit That Might Be
First, the shape of it The most recent filing shows a headline loss bigger than the...
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.